The Evolving Role of Histology in the Management of Advanced Non–Small-Cell Lung Cancer

A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)

(2017) V. A. Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC).

(2017) J. Jassem et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC).

(2017) Y. Bang et al.   JOURNAL OF CLINICAL ONCOLOGY

Accurate Classification of Non-Small Cell Lung Carcinoma Using a Novel MicroRNA-Based Approach

(2010) J. A. Bishop et al.   CLINICAL CANCER RESEARCH

Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099

(2010) Thomas J. Lynch et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer

(2010) Giorgio Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY

Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung Cancer

(2010) Shirin Khambata-Ford et al.   JOURNAL OF CLINICAL ONCOLOGY

The International Epidemiology of Lung Cancer: Geographical Distribution and Secular Trends

(2010) Danny R. Youlden et al.   Journal of Thoracic Oncology

The Prognostic and Predictive Role of Histology in Advanced Non-small Cell Lung Cancer: A Literature Review

(2010) Fred R. Hirsch et al.   Journal of Thoracic Oncology

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

(2010) Federico Cappuzzo et al.   LANCET ONCOLOGY

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

(2009) S Novello et al.   BRITISH JOURNAL OF CANCER

Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway

(2009) Kim-Son H. Nguyen et al.   Clinical Lung Cancer

Introducing Molecular Subtyping of Breast Cancer Into the Clinic?

(2009) Therese Sørlie   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer

(2009) Daniel D. Karp et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

(2009) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non–Small-Cell Lung Cancer

(2009) George R. Blumenschein et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

(2009) Alice T. Shaw et al.   JOURNAL OF CLINICAL ONCOLOGY

Diagnostic Assay Based on hsa-miR-205 Expression Distinguishes Squamous From Nonsquamous Non–Small-Cell Lung Carcinoma

(2009) Danit Lebanony et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence, Treatment Costs, and Complications of Lymphedema After Breast Cancer Among Women of Working Age: A 2-Year Follow-Up Study

(2009) Ya-Chen Tina Shih et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared With Gemcitabine Plus Carboplatin As First-Line Chemotherapy in Advanced Non–Small-Cell Lung Cancer

(2009) Bjørn H. Grønberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study

(2009) Glenwood D. Goss et al.   JOURNAL OF CLINICAL ONCOLOGY

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

(2009) Robert Pirker et al.   LANCET

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

(2009) Tudor Ciuleanu et al.   LANCET

Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib

(2009) Marie Wislez et al.   LUNG CANCER

Reasons for response differences seen in the V15-32, INTEREST and IPASS trials

(2009) Nagahiro Saijo et al.   Nature Reviews Clinical Oncology

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

(2009) Rafael Rosell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies

(2009) G. Scagliotti et al.   ONCOLOGIST

Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions

(2008) Sharon Barr et al.   CLINICAL & EXPERIMENTAL METASTASIS

Structural and Functional Basis for Therapeutic Modulation of p53 Signaling

(2008) E. A. Bassett et al.   CLINICAL CANCER RESEARCH

203 POSTER Neratinib (HKI-272), an irreversible pan-ErbB receptor tyrosine kinase inhibitor: preliminary results of a phase 2 trial in patients with advanced non-small cell lung cancer

(2008) B. Besse et al.   EJC SUPPLEMENTS

Câncer de pulmão: histologia, estádio, tratamento e sobrevida

(2008) Fabiola Trocoli Novaes et al.   Jornal Brasileiro de Pneumologia

Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies

(2008) Monica M. Mita et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors

(2008) Anne O'Donnell et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer

(2008) Mark A. Socinski et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

(2008) Giorgio Vittorio Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

(2008) Edward S Kim et al.   LANCET

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

(2008) Helena Linardou et al.   LANCET ONCOLOGY

Lung Cancer

(2008) Roy S. Herbst et al.   NEW ENGLAND JOURNAL OF MEDICINE

Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions

(2008) S. Ramalingam et al.   ONCOLOGIST